INTERVIEW: Prenatal test developer Natera sees wide Panorama
This article was originally published in Clinica
Executive Summary
The dust has settled since Natera, a maker of noninvasive prenatal tests for pregnant women, raised $54.6m in series E financing, the biggest medtech funding round of 2013 at the time (www.clinica.co.uk, 1 May 2013). Since then, this amount has been eclipsed by the $167.7m pulled in by knee implant developer ConforMIS (www.clinica.co.uk, 2 August 2013) – but the excitement over Natera’s Panorama test remains.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.